Camphor Oil Research Roundup: What the Studies Examined

Most camphor research examined isolated camphor in over-the-counter products at stated percentages, or camphor's action on sensory receptors in cells, not essential oil sold as an aromatic material. Small human studies exist, mostly measuring sensation or parent-reported symptoms. None of them tells a buyer what a bottle of undiluted oil does.

Camphor Essential Oil

Our own Camphor Essential Oil, in sizes from 0.5 oz to bulk.

From $8.69

Shop Now →

This page grades the evidence instead of summarizing claims. For each study we say what was tested, how, in whom, and what the design cannot show. Our oil is sold as an aromatic and cosmetic material, not a drug, and nothing here is advice to use it for any condition. For the wider picture of uses and sensations, see camphor oil benefits and uses: what the evidence says.

How to read camphor research: three questions before any result

Before trusting a headline, ask what was in the jar, who was measured, and what counted as an outcome. Camphor studies fail these questions often, and that matters more than the result itself.

What was the test material? Pure camphor, a branded ointment with menthol and eucalyptus oil, a liniment with methyl salicylate, or a distilled essential oil are four different things. A percent figure on a label describes a diluted product. An undiluted oil is a different exposure entirely.
Who and how? Adults breathing vapor for five minutes, children rubbed with ointment for two nights, a cell line in a dish, and an 18-person case series are not interchangeable.
What was the outcome? Reported sensation, parent-rated sleep, lab-measured airflow, and regulatory status each answer a different question.

Start with the regulators: what the FDA set, and why

The firmest facts about camphor are regulatory, and they come from safety concerns rather than benefit claims. The FDA's rulemaking history for camphorated oil lists a proposed rule on September 26, 1980 (45 FR 63869) and a final rule on September 21, 1982 (47 FR 41716), both under the heading of camphorated oil drug products (FDA rulemaking history).

The 11 percent figure is explained in a Federal Register notice of February 8, 1983 (48 FR 5852). The agency noted that the advisory panel considered camphor above 11 percent not harmful when used topically, but was concerned about poisoning if higher-strength products were swallowed by accident. Eleven percent was chosen as a maximum on that basis, and the agency reported that a marketed ointment had been reformulated from 25 percent to 11 percent (Federal Register, Feb. 8, 1983). That is a limit set for ingestion risk, not a finding that camphor works.

The current FDA monograph document for external analgesic products (M017) lists camphor in a counterirritant group at "exceeding 3% to 11%", and camphor at 0.1% to 3% among other listed ingredients (FDA OTC Monograph M017). These are rules for finished over-the-counter drug products with drug labeling. Our oil is not such a product. For the full rule-by-rule walkthrough, read FDA camphor rules explained.

The evidence-grading table

This table is our own grading, built from the sources below. "Strength" describes how much the design can support, not whether camphor is good or bad.

Topic	What was examined	Design	Strength	Main limit
Cold and tingling sensation	Camphor action on sensory channels (TRPV1, TRPA1, TRPV3)	Cell experiments; one systematic review of plant-derived ingredients in OTC cough and cold products	Mechanistic only	Dish results are not outcomes in people
Nasal sensation vs airflow	Camphor, eucalyptus or menthol vapor in adults	Small physiological study, 1983	Small human study	Short exposure; does not cover current products
Children's night-time symptoms	A commercial vapor rub vs petrolatum vs nothing	Randomized, partly blinded, 138 children, parent-rated	Moderate design, subjective outcomes	Formulation not itemized in the abstract; irritation more common
Toenail appearance	One mentholated ointment, up to 48 weeks	Case series, 18 participants, no control group	Preliminary	No comparison arm; several active ingredients
Safety of misuse	Poison-center data, case reports, a 2025 narrative review	Guideline from expert panel; reports	Consistent warning signal	Cases are not rates
Camphor essential oil as sold	Distilled oil of Cinnamomum camphora	Mostly laboratory and review literature	Little human evidence	Composition varies by chemotype and fraction

What the sensation studies show, and what they do not

Camphor is a sensory ingredient first. Xu, Blair and Clapham (Journal of Neuroscience, 2005) reported that camphor activates the TRPV1 channel at higher concentrations than capsaicin does, desensitizes it quickly, sensitizes TRPV3 and inhibits TRPA1 (Xu 2005). A 2023 systematic review in Respiratory Research pulled such findings together for menthol, camphor, eucalyptus, turpentine and thymol and described camphor as inhibiting TRPA1 and activating TRPV1 (Stinson 2023).

These are mechanism findings in cells and receptors. A channel responding in a dish says what the molecule can do to a nerve ending, and it is a long step from there to any outcome in a person.

The human sensation work points the same direction. Burrow, Eccles and Jones (Acta Oto-Laryngologica, 1983) exposed adults to camphor, eucalyptus or menthol vapor for five minutes. Measured nasal resistance to airflow did not change, yet most subjects felt cold and judged airflow improved, while exercise lowered resistance without that sensation (Burrow 1983). A 2022 narrative review of aromatic ointments reports the same split: faster nasal cooling and better reported sleep with a menthol, eucalyptus and camphor ointment, but no improvement in objective nasal airway measures (Smith 2022).

The honest reading is that camphor reliably changes how air and skin feel. Whether that sensation is useful is a separate question the data do not settle, and our chest rub explainer goes through it in more detail.

The two studies people quote most

The children's vapor rub trial

Paul and colleagues (Pediatrics, 2010) randomized 138 children aged 2 to 11 with upper respiratory infections to a vapor rub, petrolatum or nothing on the chest and neck before bed. Parents rated outcomes. The vapor rub scored best on most measures, petrolatum did not beat the no-ointment group, and irritant side effects were more common with the vapor rub (Paul 2010).

Three limits apply. Blinding was partial. Everything was parent-reported across two nights. And the abstract does not itemize the product, so the trial speaks to one commercial formulation, not to camphor alone and not to a raw oil. The same finding about irritation is a reason this trial is not a template for home use on children. Pediatric questions belong with a pediatrician or pharmacist.

The toenail case series

Derby and colleagues (Journal of the American Board of Family Medicine, 2011) followed 18 participants who used a mentholated ointment on toenails for up to 48 weeks. Fifteen of 18 showed some improvement, 5 (27.8%) had both mycological and clinical clearance at 48 weeks, 10 had partial clearance and 3 showed no change (Derby 2011). With no control group and several active ingredients, the study cannot say what camphor contributed. See our toenail fungus explainer for the fuller breakdown.

The safety evidence is more consistent than the benefit evidence

Where benefit studies are small and indirect, the harm literature repeats itself. An American Association of Poison Control Centers expert panel published an evidence-based guideline for out-of-hospital management of camphor poisoning in Clinical Toxicology in 2006, built on poison-center data of roughly 10,000 camphor ingestions a year. It advises against inducing vomiting and against activated charcoal at home, and recommends emergency referral for large ingestions, moderate or severe symptoms, or seizures (Manoguerra 2006).

A 2025 case report in BMC Pediatrics describes a one-year-old who swallowed camphor tablets and had generalized seizures before recovering with hospital care (Salcedo 2025). A 2025 narrative review of a camphor-containing vapor rub screened 220 studies, included 37, and found limited and inconclusive evidence of benefit, with many serious complications tied to misuse such as heating, swallowing, or applying near the nose, mouth or eyes (Valido 2025).

A real-world Chinese study of a multi-ingredient liniment that contains camphor and methyl salicylate enrolled 3,600 patients and reported adverse events in about 7% of them, none severe (Guo 2022). The product has several ingredients, so the camphor share cannot be isolated. In a poisoning emergency in the US, call 911 or Poison Control at 1-800-222-1222 (poison.org). Our guides to camphor oil safety and poisoning symptoms cover those situations.

Why "camphor oil" results do not transfer to one bottle

This is the part most roundups skip. Chen, Vermaak and Viljoen (Molecules, 2013) reviewed camphor from Cinnamomum camphora, noting it is obtained by distillation or chemical synthesis and that poisoning cases are documented (Chen 2013). The tree produces different chemical types, so a study of one oil does not describe another. A 2025 in vitro paper on a borneol-type C. camphora oil, for example, tested a different chemotype, found borneol the largest contributor to its reported effects, and was done in cells, not people (Xiao 2025). See chemotypes explained.

The same logic applies to our listing. Our oil is a white fraction of the wood distillate, bottled undiluted. The posted COA reports specific gravity 0.878, refractive index 1.467 and optical rotation +5.80 degrees, for batch CMPQGACCCNC003A (COA PDF). It carries no GC/MS and no camphor percentage, so even a perfect match to a study's oil could not be demonstrated from that document. That is why we do not cite any of these studies as support for the oil. Our Inside the Still page explains what is and is not on file.

Reading the next headline: a short checklist

Percent camphor on a label means a finished product, so a figure like 11 does not describe an undiluted oil.
One commercial product tested whole says little about any single ingredient.
Parent-rated or self-rated outcomes measure feeling, not airflow or lab results.
Cells in a dish show a mechanism, not a result in a person.
A review that finds the evidence "limited and inconclusive" is reporting a gap, not a negative or a positive.

If you want to see the common claims set against these limits, read camphor oil myths debunked. If you already know you want an aromatic camphor oil for scent use, the sizes run from 0.5 oz to 400 lb in the shop, with bulk details at the bulk page.

Frequently asked questions

Is there clinical proof that camphor oil works for anything?

There are small human studies of camphor-containing products measuring sensation or parent-rated symptoms, and regulatory rules for OTC drug products. There is no strong trial of undiluted camphor essential oil, and the reviews above call the benefit evidence limited.

Why is the FDA limit 11 percent?

The 1983 Federal Register notice ties the cap to ingestion poisoning risk. The panel was concerned about accidental swallowing of stronger products, and 11 percent was chosen as a maximum.

Can I use these studies to justify using the oil on skin?

No. The studies used diluted, finished products under a study protocol. Our oil is undiluted and sold as an aromatic and cosmetic material. A pharmacist or physician is the right person to ask about any health use.

Where does the evidence look strongest?

For two things: that camphor strongly affects sensory channels, and that swallowing it is dangerous, especially for young children. The rest is thin.